Entrada Therapeutics (NASDAQ:TRDA – Get Rating) is one of 950 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Entrada Therapeutics to related businesses based on the strength of its earnings, profitability, risk, valuation, institutional ownership, dividends and analyst recommendations. Analyst Recommendations This is […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) major shareholder Bros. Advisors Lp Baker purchased 2,643 shares of the firm’s stock in a transaction that occurred on Thursday, June 2nd. The stock was bought at an average price of $5.82 per share, for a total transaction of $15,382.26. Following the purchase, the insider now owns 4,467,393 […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) major shareholder Bros. Advisors Lp Baker bought 38,304 shares of the stock in a transaction on Monday, June 6th. The stock was purchased at an average cost of $6.41 per share, with a total value of $245,528.64. Following the purchase, the insider now directly owns 4,501,658 shares of […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) major shareholder Bros. Advisors Lp Baker bought 16,849 shares of the stock in a transaction dated Friday, May 20th. The shares were bought at an average price of $5.84 per share, for a total transaction of $98,398.16. Following the completion of the acquisition, the insider now owns 4,436,709 […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) major shareholder Bros. Advisors Lp Baker bought 7,837 shares of the stock in a transaction on Monday, May 23rd. The shares were acquired at an average cost of $5.99 per share, with a total value of $46,943.63. Following the purchase, the insider now owns 4,443,719 shares of the […]